Analysis of germline and somatic PTEN profiles and their role in the racial disparity in endometrial cancer outcome by Liang, Margaret
  
 
 
 
 
 
 
Analysis of Germline and Somatic PTEN Profiles and their Role 
in the Racial Disparity in Endometrial Cancer Outcome 
 
A Senior Honors Thesis 
 
Presented in Partial Fulfillment of the Requirements for graduation with distinction in 
Biology in the undergraduate colleges of The Ohio State University 
 
by 
 
Margaret Liang 
 
The Ohio State University 
August 2006 
 
Project Advisors: 
Wolfgang Sadee, Dr. rer. Nat., Department of Pharmacology 
Charis Eng, MD, PhD., Genomic Medicine Institute, Cleveland Clinic Foundation, and 
Department of Genetics, Case Western Reserve University School of Medicine, 
Cleveland, OH 
 
 
 
 2
ABSTRACT 
Endometrial cancer is the most common gynecological malignancy in the United 
States. Poorer prognosis and higher mortality rates for endometrial cancers in African-
Americans compared to those in whites have revealed a racial disparity in this disease. In 
contrast to other solid tumors, several studies paradoxically have supported somatic 
PTEN mutations and microsatellite instability (MSI) as favorable prognostic features. 
The aim of this study was to determine whether there is a racial disparity in the frequency 
of these molecular alterations that may contribute to differences in endometrial cancer 
outcome.  
 We scanned paired germline and tumor DNA from 53 endometrial cancer 
patients for somatic mutations in the PTEN gene, loss of heterozygosity (LOH) around 
10q22-q24, and global MSI according to Bethesda recommendations. Fourteen somatic 
mutations were found in 8 of 26 (31%) tumors from African-American (AA) individuals 
and were almost exclusively a feature of endometrioid cases (11 of 14 mutations; 79%). 
Eleven somatic PTEN mutations were found in 7 of 27 tumors (26%) from white women 
(NAA), with 5/11 of the mutations (45%) present in endometrioid cases. Of the 25 
informative AA samples, 15 (60%) exhibited LOH at one or more loci, while LOH was 
observed for at least one locus in 19 of 26 (73%) informative NAA samples. Consistent 
with previous studies, 5/25 (20%) AA and 5/26 (19%) NAA patients were MSI-positive.  
In addition, 10 single nucleotide polymorphisms (SNPs) and their reconstructed 
haplotypes were examined as host factors to investigate the association of specific 
genomic regions of the PTEN locus with endometrial cancer and its prognosis. Most 
importantly, the distribution of haplotypes revealed significant differences between the 
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two racial groups (χ2= 13.814, P = 0.032). In particular, haplotype 3, CTIAGTATCC, 
was most clearly over-represented in AA (37%) compared to NAA (15%, P = 0.014). 
The results of this study confirmed previous evidence that somatic PTEN 
mutations are associated with the favorable endometrioid histology (P = 0.015), 
irrespective of race. Additionally, novel differences were observed between the two racial 
groups in the PTEN haplotype analysis. Although no specific associations were found in 
this limited haplotype analysis, haplotype 3 was identified as a candidate for further study 
as a germline component in endometrial cancers that perhaps may predispose AA to 
certain unfavorable prognostic factors and thus contribute to the racial differences in 
outcome. A trend among the haplotype distribution was also observed between the 
endometrioid and non-endometrioid study groups (χ2= 11.870, P = 0.065), further 
suggesting that certain haplotypes perhaps could affect histology and consequently 
influence the racial disparity. Taken together, we conclude that none of the somatic 
molecular alterations per se independently account for the observed racial disparity in 
endometrial cancer outcome; however, cumulatively, these data suggest that genetic 
factors likely contribute to this disparate clinical outcome, perhaps additively or acting in 
concert, and certainly require further investigation. 
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INTRODUCTION 
 Endometrial cancer is the most common type of uterine cancer as well as the most 
common cancer of the female reproductive system in the United States, accounting for 
6% of all women’s cancers (1). While the mortality rate among white women has 
decreased over the past 20 years, it has remained constant among other racial groups. In 
particular, the mortality rate of African-American women with endometrial cancer is 
nearly two-fold higher than that of whites despite a slightly lower incidence. From 2000-
2003, the National Cancer Institute reported age-adjusted endometrial cancer incidence of 
19.5/100,000 African-American women and 23.3/100,000 white women; however, the 
mortality rates for these years were 7.1/100,000 African-American women with 
endometrial cancer and only 3.9/100,000 white women with the same disease (2). 
Moreover, in their 1996-2002 review, the five-year relative survival was only 60% in 
African-American patients with endometrial cancer compared to 85% in white women 
with this disease. Together, these data strongly suggest a disparity between race and 
endometrial cancer outcome.   
 The basis for this disparity is currently being investigated. While progress has 
been made towards elucidating the epidemiology and natural history involved, its 
mechanism remains largely unknown. One factor which has been shown to be associated 
with the less favorable prognosis observed in African-American women is the difference 
in usage of estrogen replacement therapy, which is more often prescribed to white 
patients (3, 4, 5). While use of this hormone in an unopposed manner increases the risk of 
endometrial cancer, estrogen-induced cancers are usually well differentiated; thus, 
estrogen replacement therapy is associated with favorable tumor grade and contributes to 
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better survival in whites. Progestational agents, however, can be added to decrease 
endometrial proliferation and increase PTEN expression, which is why most hormone 
replacement therapies use a combination of estrogen and progesterone (6, 7). The poor 
outcome in African-Americans with endometrial cancer can also be attributed to the 
higher frequency of unfavorable prognostic features. African-Americans are more often 
diagnosed with poorly differentiated, deeply invasive, aggressive, and advanced stage 
tumors (8-14). Data demonstrating that African-Americans tend to receive delayed 
diagnosis and less aggressive treatment suggest that providing these patients with 
improved health care could improve their endometrial cancer survival and might partially 
explain their more frequent presentation at an advanced stage (11, 12, 13). African-
Americans have a higher incidence of more aggressive type II tumors, including serous, 
mixed epithelial, and mixed mullerian tumors, rather than less aggressive type I 
endometrioid carcinomas, which occur more frequently in whites (8-14). The etiology of 
type II carcinomas differs from that of the most common type I endometrioid carcinomas 
(15, 16). Hence, racial disparity in outcome may reflect differences in etiologic exposure, 
genetics, or other factors that lead to higher rates of aggressive tumors (17). 
Recent studies have offered several genetic explanations for the racial disparity in 
endometrial cancer. The p53 protein regulates cell-cycle inhibition and apoptosis in 
response to DNA damage; thus, mutation or deletion of TP53 resulting in loss-of-
function often leads to uncontrolled cell growth (18, 19). Contrary to the rapidly 
degraded p53 in normal cells, the altered protein resists degradation and accumulates in 
the nucleus, where it can be detected by immunohistochemistry as p53 overexpression 
(18, 20). Studies have shown that p53 overexpression occurs more frequently in African-
 6
American women and is an independent variable associated with poor survival as well as 
a potential predictor of recurrence (21-24). The p27 protein, a cyclin-dependent kinase 
inhibitor also involved in regulating the cell cycle, is thought to play a similar role in 
endometrial carcinogenesis, but its role has been less widely studied (25). 
The phosphatase and tensin homolog gene (PTEN), located at 10q23.3, is a 
ubiquitously expressed tumor suppressor phosphatase that mediates cell cycle arrest and 
apoptosis (26, 27). It is involved in the pathogenesis of many types of sporadic solid 
tumors. Germline PTEN mutations have been found in 85% of classic Cowden 
Syndrome, a heritable, multiple hamartomatous tumor syndrome associated with high 
risk of breast, thyroid, and endometrial carcinomas (27, 28, 29, 30). Somatic mutations 
and/or deletions of PTEN as well as non-genetic PTEN inactivation have been shown to 
play a major role in the initiation of endometrial cancer, suggesting that these events 
occur early in endometrial carcinogenesis, prior to the loss of normal differentiation or 
histology (31, 32). As the tumors transition from premalignant to malignant disease, 
additional PTEN damage accumulates. Thus, immuohistochemical methods can be used 
to detect loss of PTEN expression and used as an informative biomarker for endometrial 
neoplasia, including precancerous lesions. PTEN is mutated in ~30-40% of endometrial 
cancers (31, 33). Previous studies have found that somatic mutations in PTEN are four-
fold more frequent in tumors from whites relative to those from African-Americans and 
are associated with favorable survival in advanced endometrial cancer (34, 35). Thus, 
PTEN and the chromosome region in which it resides are excellent candidates for the 
genetic analysis of endometrial cancer as it relates to racial disparity in presentation and 
outcome.  
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In another heritable cancer syndrome, hereditary non-polyposis colorectal cancer, 
endometrial carcinoma is the most common extra-colonic cancer, exceeding the 
incidence of colorectal cancer in women carriers (36, 37). In this syndrome, germline 
mutations of DNA mismatch repair genes often lead to microsatellite instability (MSI) 
(38, 39). Occurring in ~20% of cases with endometrial cancer, MSI has been associated 
with endometrioid histology and thus identified as a favorable prognostic feature for 
endometrial cancer (34, 38). Taken together, both somatic PTEN mutation and MSI status 
constitute somatic genetic factors that potentially play a role in endometrial cancer 
progression and may even contribute to the racial disparity seen in this disease. 
Previous association studies on this subject have focused primarily upon 
individual single nucleotide polymorphisms (SNPs). Taking advantage of linkage 
disequilibrium (LD), haplotype-based studies have the potential to provide much more 
powerful results. LD involves the coinheritance of SNPs that possess strong allelic 
associations and results in block-like segments, or haplotypes, which are passed through 
generations (40). Each discrete block is bounded by regions of historical recombination 
and contains only a few common haplotypes. These common haplotypes often occur at 
varying frequencies among racial groups when populations have been separated and new 
mutations have not had much opportunity to spread; therefore, the distribution of 
haplotypes may provide clues to underlying genetic differences in AA and NAA with 
endometrial cancer. 
In order to clarify the molecular pathogenesis of this disparity, we chose to 
examine the differences in various somatic and germline PTEN profiles along with global 
MSI of African-Americans compared to those of whites. This study confirmed previous 
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findings regarding endometrial cancer, including the association between PTEN mutation 
and the more favorable endometrioid histology, irrespective of race (34, 35). Moreover, 
statistically significant differences between AA and NAA were observed among the 
PTEN SNP haplotype distributions, identifying common haplotypes and trends that with 
further investigation may be found to play a role in the disparate outcomes of these two 
groups. Undoubtedly complex, this racial disparity in endometrial cancer appears to 
involve numerous molecular alterations in need of more detailed study. 
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MATERIALS AND METHODS 
Patients. Fifty-three patients, consisting of 26 self-described African-Americans 
(AA) and 27 whites of Western European descent (NAA) with endometrial cancer, were 
included in the present study. The study was designed to match both racial groups for 
tumor histology and FIGO* stage. Each group was made up of 12 endometrioid cases 
(~45%), 2 mixed epithelial cases (~8%), and 7 serous cases (~26%). Additionally, 5 and 
6 mixed mullerian tumor cases (~21%) were included from each respective ethnic group. 
The AA group consisted of 18 cases with Stage I tumors (69%), 2 cases with Stage II 
tumors (8%), 5 cases with Stage III tumors (19%), and 1 case with a Stage IV tumor 
(4%). Of the NAA, 19 were Stage I (70%), 3 were Stage II (11%), 4 were Stage III 
(15%), and 1 was Stage IV (4%). Age at diagnosis ranged from 36 to 87 years for all 
patients. Germline and tumor DNA from each patient were isolated from paraffin-
embedded tissue blocks by standard techniques (41). 
PTEN Mutation Analysis. PTEN mutation analysis of all nine coding exons, 
exon-intron junctions, and flanking intronic sequences was performed for both germline 
and tumor DNA using PCR-based denaturing gradient gel electrophoresis (DGGE). For 
the initial PCR, each 25 µl reaction mixture contained 20 ng of template DNA, 12.5 µl of 
HotStarTaq Master Mix (Qiagen, Valencia, CA), and 10mM of each primer pair. Primer 
sequences can be found in Table 1.1. Amplification was performed using the following 
protocol: 15 min initial denaturation at 94°C, followed by 35 cycles of 30 s at 94°C, 45 s 
at 55°C, and 45 s at 72°C, and finally 72°C for 10 min, 98°C for 8 min, 55°C for 30 min, 
and 40°C for 30 min. The samples were then subjected to electrophoresis on a 10% 
 
* International Federation of Gynecology and Obstetrics 
 10
polyacrylamide gel containing 5% glycerol and a linear 15-50% urea-formamide gradient 
at 100V for 16 hours at 60°C (42). The gels were stained using ethidium bromide and 
PCR products were visualized by UV transillumination. DNA from bands identified as 
aberrant served as the template for fluorescence-based sequencing using BigDye v3 
(Applied Biosystems, Foster City, CA). Sequencing products were electrophoresed using 
an ABI 3730 DNA Analyzer (Applied Biosystems) and analyzed using the Sequencher 
software program (Gene Codes, Ann Arbor, MI) in order to determine the exact nature of 
each mutation/variation. 
Loss of Heterozygosity Analysis. DNA from carcinoma and adjacent germline 
tissue was amplified using primers that define 4 highly polymorphic microsatellite 
markers along the PTEN locus (average heterozygosity > 0.75): D10S1765, 
AFMa086wg9, D10S541, and D10S583 (Figure 1). Primer sequences are listed in Table 
1.2. Forward primers were fluorescently labeled with HEX, FAM, or TET at the 5’-
position. The PCR cycling conditions were as follows: 15 min denaturation at 95°C, then 
40 cycles of 94°C for 30 s, 50°C for 45 s, and 72°C for 1 min, and a final extension at 
72°C for 10 min. The PCR products were electrophoresed using an ABI 3730 DNA 
Analyzer (Applied Biosystems) and loss of heterozygosity (LOH) was analyzed using 
GeneMapper v3.5 software (Applied Biosystems). The ratio T1:T2/N1:N2 was 
calculated, where T and N represent tumor and normal, respectively, and 1 and 2 
designate each allele. Cases in which this ratio was less than 0.67 or greater than 1.5 were 
considered to demonstrate LOH (42). For each sample, overall LOH was scored when 
one or more of the panel of four polymorphic loci showed LOH, as is standard. 
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Microsatellite Instability Analysis. To determine whether MSI was present, five 
polymorphic microsatellite markers were amplified in paired endometrial tumor and 
germline DNA samples using PCR. The five markers constitute part of the Bethesda 
Guidelines, which were developed by an international workshop hosted by the National 
Cancer Institute on genetic screening of HNPCC (43). Two loci were mononucleotide 
poly(T) and poly(A) runs (BAT25 and BAT26, respectively) and three loci contained CA 
dinucleotide repeats (D2S123, D5S346, and D17S250). Primer sequences for the markers 
are located in Table 1.3. Forward primers were 5’-labeled with HEX, FAM, or TET. 
Amplification was performed using 15 min denaturation at 95°C, then 40 cycles of 94°C 
for 30 s, 55°C for 45 s, and 72°C for 1 min, and a final extension for 10 min at 72°C. The 
PCR products were electrophoresed as previously described and the resulting data was 
analyzed using GeneMapper v3.5 software (Applied Biosystems, Foster City, CA).  
The overall microsatellite status of each sample was determined based on the 
percentage of unstable loci. According to updated Bethesda recommendations, samples 
were defined as MSI-positive when at least 60% (3 out of 5) of the markers displayed 
instability (43). Only cases showing explicitly distinct additional peaks or shifts in tumor 
DNA in comparison to germline DNA were classified as unstable. A sample was 
classified as MSI-negative when it did not meet this criterion.    
Linkage Disequilibrium and Haplotype Analysis. We analyzed 10 previously 
mapped SNPs (with a minor allele frequency ≥0.10) in germline DNA from all 53 
patients. SNPs were spaced approximately one every 15 kb across a 147 kb region 
spanning the PTEN locus (Table 2). The amplification procedure was as follows: 15 min 
denaturation at 95°C, then 34 cycles of 94°C for 30 s, 55°C for 45 s, and 72°C for 1 min, 
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then a final extension for 10 min at 72°C. SNPs were genotyped using either fragment 
analysis, restriction fragment length polymorphism (RFLP), or SnaPshot primer 
extension methods. Primer sequences and genotyping methodologies are provided in 
Table 1.4. Fragment analysis and SNaPshot products were electrophoresed on an ABI 
3730 DNA Analyzer (Applied Biosystems) and analyzed using GeneMapper v3.5 
software (Applied Biosystems). 
Following assessment of Hardy-Weinberg equilibrium (HWE) at each 
polymorphic locus, pairwise LD coefficients (Lewontin’s D’) were estimated using the 
LDmax software program and visualized using the GOLD graphical interface (44). D’ 
was calculated and plotted separately for each sample population (AA and NAA). 
Haplotypes consisting of the 10 SNPs were reconstructed for all samples using the 
PHASE v2.1 software program. 
Statistical analysis. Statistical analysis was performed using Fisher’s exact test. 
Differences were considered significant if the two-tailed P-value was <0.05. Haplotype 
frequencies were compared using a Pearson χ2 test. Rare haplotypes with expected 
frequency of ≤2 in both study groups were pooled together to make the chi-square 
approximation accurate. A P-value of <0.05 was considered significant. 
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RESULTS 
PTEN Mutation Analysis. Fifty-three samples (26 AA and 27 NAA) had 
sufficient material for mutational analysis of the entire PTEN gene. Fourteen somatic 
mutations were found in 8 of 26 (31%) AA tumors compared to 11 somatic PTEN 
mutations identified in 7 of 27 (26%) NAA tumors (Table 3). While the frequency of 
PTEN mutations did not reveal a racial difference (P = 0.766), an association was 
observed with more favorable tumor histology (P = 0.015), irrespective of race. PTEN 
mutation was identified in 11/24 (46%) endometrioid tumors and only 4/29 (14%) non-
endometrioid tumors (Table 4.1). Interestingly, this association was primarily attributable 
to the AA population as it was statistically significant in the AA group (P = 0.009), but 
not in the NAA group (P = 0.662). Previous studies have shown that somatic PTEN 
mutations tend to occur more frequently in MSI-positive endometrial cancers because 
MSI predisposes the mononucleotide repeats in exons 7 and 8, and to a lesser extent exon 
5, to be hypermutable (31, 45). After testing for association between PTEN mutation and 
MSI status (P = 0.135), the favorable endometrioid histology appears to be primarily 
PTEN mutation-associated and not MSI-dependent in the present study (Table 4.2). 
Loss of Heterozygosity Analysis. We analyzed 51 endometrial cancers (25 AA 
and 26 NAA) for which tumor and corresponding germline DNA were available using 
four highly polymorphic markers flanking (D10S1765, D10S541, D10S583) and within 
(AFMa086wg9) PTEN (Fig. 1). Of the 25 AA samples, all of which possessed at least 
one informative marker, 15 (60%) exhibited LOH at one or more loci. Among the 26 
NAA samples, all of which had at least one informative marker, 19 (73%) displayed LOH 
at one or more loci. No significant difference in LOH status was observed in 10q22-q24 
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between the two racial groups (P = 0.382) (Table 4.1, Figure 2). Also, MSI did not occur 
at a higher frequency in those carcinomas that were not characterized by LOH. These 
observations act as a positive control on our MSI and LOH designations as the presence 
of MSI can often confound calling LOH status. 
Microsatellite Instability Analysis. Using the Bethesda panel of five 
microsatellite markers (BAT25, BAT26, D2S123, D5S346, D17S250), we analyzed MSI 
within 51 endometrial cancers (25 AA and 26 NAA), for which tumor and corresponding 
germline DNA were available. Of the 25 AA samples, 5 (20%) were MSI-positive 
(Figure 3). Out of the 26 NAA samples, 5 (19%) were MSI-positive. While no significant 
difference was found regarding MSI status between AA and NAA patients (P > 0.99), 
20% of all endometrial cancers in this study were classified as overall MSI-positive, 
which agrees with previous findings (Table 4.1) (34, 38). 
Linkage Disequilibrium and Haplotype Analysis. We then sought to determine 
if host differences in and around the PTEN locus were responsible for the racial disparity 
in endometrial carcinoma.  First, it is important to note that no significant departures from 
HWE were observed for either population (data not shown). The existence of HWE in 
both our patient groups serves as a quality control check on genotyping procedures, 
providing evidence that the sampling probably was unbiased and there probably were not 
problems in laboratory procedure. Also, HWE is a guide that we can use analysis 
procedures that are dependent on these conditions. For the AA population, moderate LD 
existed between SNPs 2 and 6 (D’ = 0.802), SNPs 2 and 9 (D’ = 0.809), and SNPs 6 and 
10 (D’ = 0.832) (SNPs are noted in Tables 1.4 and 2). In the NAA population, moderate 
LD was observed between SNPs 1 and 10 (D’ = 0.710, SNPs 2 and 10 (D’ = 0.868), 
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SNPs 4 and 10 (D’ = 0.868), SNPs 6 and 10 (D’ = 0.868), SNPs 7 and 8 (D’ = 0.877) and 
SNPs 9 and 10 (D’ = 0.759). In this same population, low LD was observed between 
SNPs 5 and 10 (D’ = 0.566). Excluding these unique areas of moderate/low LD, our data 
show that the PTEN locus is primarily characterized by strong LD (D’ = 1.00) (Figure 4). 
Because of this, we chose to reconstruct extended haplotypes for both patient groups 
using all 10 SNPs (Table 5.1). For AA, the 4 most common haplotypes capture >80% of 
those observed. The same 4 common haplotypes with the addition of haplotype 5 account 
for >80% of those observed in the NAA population. The haplotype distribution between 
AA and NAA revealed significant racial differences in this study (χ2 = 13.814, P = 0.032) 
(Table 5.1). The most distinct difference was observed for haplotype 3. While 37% of 
AA haplotypes existed as haplotype 3, only 15% of NAA haplotypes were present in this 
form (P = 0.014). Also, there was a trend for the association between the observed 
haplotype distribution and tumor histology (χ2= 11.870, P = 0.065). Upon further 
analysis, trends were identified between haplotype 3 and unfavorable tumor stage (P = 
0.178) as well as non-endometrioid histology (P = 0.375). Unfavorable tumor stage was 
defined as FIGO stages IC or higher, in which the cancer has invaded >50% of the 
myometrium. In addition, a trend was observed for haplotype 3 and absence of LOH at 
10q22-q24 (P = 0.148). Of the other common haplotypes, there was a trend for haplotype 
1 to be over-represented in the AA group (35%) compared to the NAA group (24%) (P = 
0.287). Conversely, there was a trend for haplotypes 2 and 4 to be under-represented in 
the AA population (6% for both) in comparison to the NAA population (17% and 15%, 
respectively) (P = 0.124 and 0.202, in that order). Interestingly, there was an association 
between haplotype 2 and endometrioid histology (P = 0.034, Table 5.2).  
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DISCUSSION 
 African-American women have a lower incidence of endometrial cancer than 
white women, but their disease-related mortality is significantly higher (1). Although this 
disparity in survival is partially attributable to the fact that African-American women are 
more frequently diagnosed with metastatic disease, their survival is significantly worse in 
both early and advanced stages (11). In cases where the time from onset of abnormal 
uterine bleeding to diagnosis and intensity of treatment have been the same, this disparity 
in outcome has been observed (46). Studies have demonstrated that aggressive tumor 
types account for a higher percentage of total malignancies among African-Americans 
compared to whites (8-14). This represents only one of the numerous unfavorable 
prognostic features more common among African-Americans, including poorly 
differentiated, deeply invasive, and advanced stage tumors. For type I and type II 
endometrial cancers, the developmental pathways are fundamentally different. Pure 
serous carcinomas typically arise directly from atrophic endometrium, rather than from 
endometrial hyperplasia (15, 16). Also, serous carcinomas are less strongly related to 
high body mass index, exogenous estrogen use, and elevated serum levels of estrogenic 
hormones in comparison to endometrioid cancers. Because African-Americans have a 
much lower incidence of endometrioid adenocarcinoma than do whites, it may be that 
African-Americans are less exposed to estrogens and therefore more likely to develop the 
aggressive tumors that arise from atrophic endometrium (47). Higher frequency of 
aggressive tumors may be caused by other differences in etiologic exposure and genetics. 
Thus, it is of interest to investigate possible racial differences in the molecular 
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pathogenesis of endometrial cancer that may underlie the disparity in outcome between 
African-Americans and whites with this disease. 
A few molecular alterations have already been identified as genetic factors that 
likely contribute to the racial disparity in endometrial cancer outcome. The p53 protein 
plays an important role in cell cycle regulation and apoptosis in response to DNA damage 
(18, 19). Thus, TP53 mutation often leads cells to uncontrolled growth and is involved in 
the pathogenesis of numerous cancers. A mutation in TP53 can typically be detected 
using immunohistochemical staining because mutant p53 resists degradation and 
accumulates in the nucleus, whereas p53 in normal cells is quickly degraded and unable 
to be detected via this method (18, 20). The resulting overexpression of p53 occurs at a 
significantly higher frequency for African-Americans in both early and advanced stage 
tumors (22, 23. 24). Overexpression of mutant p53 occurs in ~20% of endometrial 
cancers and is associated with non-endometrioid histology, advanced stage tumors, and 
poor outcome. Studies have demonstrated that p53 alterations are correlated with both 
rapid progression and shorter overall survival (48). Moreover, evaluation of adjuvant 
treatment showed that p53 overexpression was associated with resistance to platinum-
based chemotherapy, providing further support that dysfunctional p53 cannot mediate the 
apoptotic process (49). When comparing only patients with advanced stage carcinomas 
and mutant p53 overexpression, African-American survival is still worse than in whites, 
which suggests other genetic factors contribute to the racial disparity (22). In this regard, 
both PTEN mutation and MSI have been identified previously as favorable prognostic 
factors, although their potential role in this disparity has not been fully elucidated (34-35, 
38, 50). 
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 In the present study, we have extended this line of investigation by examining 
whether there are racial differences in the incidence of somatic PTEN mutations/deletions 
and MSI in endometrial cancers. Both of these molecular alterations have been associated 
with endometrioid histology, which is a favorable prognostic factor; however, a unique 
feature of our investigation was that both tumor type and stage between the two racial 
groups were almost completely matched. In addition to somatic genetic factors, we were 
also able to analyze if germline PTEN variation (host factors) could account for this 
disparity by looking at LD among 10 carefully selected SNPs in the PTEN region and 
their extended haplotypes. 
The PTEN gene encodes a tumor suppressor phosphatase that signals down the 
phosphoinositol-3-kinase (PI3K)/AKT pathway and affects apoptosis and cell cycle arrest 
(51, 52). Somatic mutations and/or deletions of the PTEN gene occur in ~30-40% of 
endometrial cancers and also play a role in the initiation of endometrial carcinomas (31, 
32, 33). These alterations have been observed in the normal-appearing endometrial gland 
and in endometrial pre-cancers (31, 32). In previous studies, PTEN mutations have been 
observed in whites up to four times more frequently than in African-Americans and are 
associated with favorable survival in advanced endometrial cancer (34, 35). Moreover, 
germline PTEN mutations are associated with Cowden Syndrome, a heritable cancer 
syndrome associated with an increased risk of developing endometrial cancer (28, 29, 
30). To date, germline PTEN mutations have been identified in 85% of patients 
diagnosed with Cowden Syndrome. 
In the present study, somatic PTEN mutations were detected in tumors from 31% 
of AA and 26% of NAA patients. No racial differences among carriers of PTEN 
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mutations were observed (P = 0.766). Evidence from other studies, however, has 
demonstrated that a racial difference in molecular alterations does exist (34). These 
studies propose that TP53 may be a more frequent target for mutations than PTEN in 
African-Americans, resulting in higher frequencies of non-endometrioid, advanced stage 
endometrial cancers, whereas, PTEN may be a more frequent target in whites and thus 
endometrioid, early stage cancers predominate (34).  However, our studies do not support 
this hypothesis most likely because we were careful to control for histology and FIGO 
stage across both AA and NAA. Consistent with previous studies, a correlation was 
observed between the presence of somatic PTEN mutation and endometrioid histology (P 
= 0.015), the latter of which is a favorable prognostic feature, irrespective of race. Out of 
all endometrioid carcinomas in this study, 46% exhibited somatic PTEN mutations 
compared to only 14% of non-endometrioid carcinomas. Thus, it is possible that the 
previously published hypothesis that higher frequency of somatic PTEN mutations 
correlates with better prognosis may be instead due to histologic difference alone. What 
accounts for histology, however, is currently unknown. 
We were also able to verify the prevalence of LOH in the PTEN region among 
patients with endometrial cancers. LOH does not appear to contribute to the racial 
disparity (P = 0.382), as 60% of AA tumors and 73% of NAA tumors exhibited LOH. 
These data do indicate that PTEN is a commonly-mutated gene in endometrial cancers 
and is likely to exert a significant influence upon carcinogenesis (31, 33). However, 
because PTEN and p53 interact at several levels, the real molecular-based etiology to 
racial disparities in endometrial cancer outcome will not be straightforward. For example, 
p53 has been shown to act as a transcription factor for PTEN (53). Yet, PTEN has been 
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shown to autoregulate its own expression by stabilizing p53 regulation of itself in a 
phosphatase-independent manner (53).  Paradoxically, when PTEN and p53 interact, p53 
is stabilized but PTEN is degraded (55). 
In order to assess global MSI, two mononucleotide repeat and three dinucleotide 
repeat microsatellite markers suggested by the Bethesda Guidelines were analyzed for 
instability. Because of their repetitive sequence, these markers have an increased 
susceptibility to mutation during DNA replication. Most of these mutations are normally 
recognized and corrected by a family of DNA mismatch repair enzymes (56). 
Approximately 20% of endometrial cancers, however, have mutations in multiple 
microsatellite sequences attributable to inactivation of the MLH1 DNA repair gene (57, 
58). Although the MLH1 gene is generally inactivated by mutations in syndromes such as 
HNPCC, inactivation of MLH1 in sporadic endometrial cancers as well as colorectal 
cancers is caused by methylation of the promoter region of the gene, resulting in 
inhibition of transcription. As expected, MSI was identified in ~20% of the AA and NAA 
patient groups in the present study (38, 59, 60). These data suggest that MSI in and of 
itself is not responsible for the observed racial disparity (P > 0.99), which is in agreement 
with previous studies. In general, MSI-positive endometrial cancers have a high 
frequency of inactivating frameshift mutations in genes with coding region microsatellite 
repeats, which likely represents the primary means through which MSI contributes to 
endometrial carcinogenesis (31, 45). A major genetic explanation for the association 
between MSI and favorable prognosis is that MSI-positive cancer cells have a nucleotide 
mutation frequency two to three orders of magnitude higher than that of MSI-negative 
cancer cells, resulting in rapid accumulation of MSI-induced genome damage above the 
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threshold for cell viability and subsequent activation of apoptotic pathways or increased 
susceptibility to antineoplastic therapeutic agents (61, 62). Thus, these cancer cells are 
prone to decreased editing function and/or lose their evolutionary fitness for survival 
before the host dies as a result of the disease. In a related hypothesis, endometrial cancers 
with MSI acquire a unique spectrum of somatic molecular genetic alterations. MSI-
negative carcinomas typically acquire TP53 mutation, which is associated with type II 
endometrial cancers and poor prognosis (35, 59, 63, 64). Much like the hypothesis 
regarding somatic PTEN mutation and favorable histology, inactivation of PTEN is more 
common in MSI-positive carcinomas and is generally associated with type I endometrial 
cancers as well as improved prognosis (35, 65).  
In order to determine if host-related PTEN variation may account for the disparate 
prognoses, SNPs within and near the PTEN locus and their corresponding haplotypes 
were analyzed in this study. Because haplotype-based association studies are much more 
powerful than traditional association studies, which focus upon individual SNPs, we 
chose to examine the coinheritance of SNPs in tight LD and their corresponding extended 
haplotypes. Statistically significant differences between the two racial groups were 
observed in terms of haplotype distribution (χ2= 13.814, P = 0.032). Among the four 
common haplotypes shared by AA and NAA, the most substantial difference was 
observed for haplotype 3. This haplotype was over-represented in the AA population 
(37%) compared to the NAA population (15%). These haplotype differences represent 
potential areas of interest for further study since they account for a good portion of the 
racial differences in haplotype distribution. We then sought to determine whether certain 
trends in distribution of haplotype 3 between the two racial groups may predispose AA to 
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non-endometrioid histology or advanced tumor stage and in this manner affect disparate 
outcome. While significant associations were not found for haplotype 3 in relation to 
tumor histology or stage, trends were observed, suggesting that in a larger study this 
haplotype may help influence AA to acquire unfavorable prognostic features. Moreover, 
the observed trend among haplotype distribution in relation to tumor histology (χ2= 
11.870, P = 0.065) provides additional support for further investigation. Host factors may 
interact perhaps with the environment, as hormonal milieu differences are known to exist 
between AA and NAA, resulting in a certain unfavorable histology that is manifest in this 
apparent racial disparity. Finally, as with all studies involving AAs, admixture must also 
be considered as this can confound SNP/haplotype analyses. Due to variation in 
admixture levels among AA individuals, association studies may be inadvertently subject 
to stratification bias (66). 
Survival of African-American women with endometrial cancer is consistently 
worse than that of whites with the same disease despite improving health practices. The 
cause of this disparity is complex and undoubtedly involves behavioral and 
environmental risk factors, inherited susceptibility, as well as acquired molecular 
alterations. By increasing our understanding of specific molecular variations that may 
distinguish endometrial cancer carcinogenesis within AA and NAA, detection of these in 
pre-cancers may help us to more effectively identify patients at risk of developing 
endometrial cancer. Customized medical treatments may eventually be tailored to a 
patient’s genetic profile, taking into account his or her racial ancestry, and will be capable 
of improving disease prevention, diagnosis, and treatment. In the present study, a racial 
difference was not found for mutation or LOH in the PTEN region or global MSI. This 
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study benefited from having AA and NAA series that were matched by stage and 
histology; however, its weakness came from its small sample size. Despite the small 
sample sizes, we were able to confirm certain previously published findings, including 
the association between PTEN mutation and endometrioid histology, irrespective of race, 
and the incidence of MSI in 20% of endometrial cancers. These observations serve as a 
positive control and perhaps suggest that although small, our series does reflect the larger 
population-at-large to a certain extent. What is novel in our study are the significant 
differences among PTEN haplotype distribution between the two groups, which suggest 
the potential role SNPs and their associated haplotypes may play in the study of this 
health disparity. Furthermore, if a haplotype is found to occur more frequently in affected 
individuals than unaffected individuals, there is a high probability that a genetic variant 
located within that region through LD is related to endometrial cancer development. 
Thus, we propose to perform equivalent haplotyping in AA and NAA without 
endometrial cancer to see if the association holds. Clearly, several pathways affect the 
development of endometrial cancer and a better understanding of specific genetic 
differences between AA and NAA is essential if we hope to decrease the disproportionate 
mortality rate of African-American women with endometrial cancer.  
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TABLES 
Table 1.1 – Primer sequences for PTEN mutation analysis using DGGE. 
PTEN 
Exon 
Primer Sequence* 
E1 F 5’-CGT CTG CCA TCT CTC TCC TCC T-3’ 
E1 R 5’-CGC CCG CCG CGC CCC GCG CCC GGC CCG CCG CCC CCG CCC 
GAA ATA ATA AAT CCG TCT ACT CCC ACG TTC T-3’ 
E2 F 5’-CGT CCC GCG TTT GAT TGC TGC ATA TTT CAG-3’ 
E2 R 5’-CGC CCG CCG CGC CCC GCG CCC GTC CCG CCG CCC CCG CCC 
GTC TAA ATG AAA ACA CAA CAT G-3’ 
E3 F 5’-CGC CCG CCG CGC CCC GCG CCC GGC CCG CCG CCC CCG CCC 
GTA AAT GGT ATT TGA GAT TAG-3’ 
E3 R 5’-GCG CGA AGA TAT TTG CAA GCA TAC A-3’ 
E4 F 5’-CGC CCG CCG CGC CCC GCG CCC GGC CCG CCG CCC CCG CCC 
GAA ATA ATA AAC ATT ATA AAG ATT CAG GCA ATG-3’ 
E4 R 5’-GAC AGT AAG ATA CAG TCT ATC-3’ 
E5.1 F 5’-CGC CCG CCG CGC CCC GCG CCC GTC CCG CCG CCC CCG CCC 
GTT TTT TCT TAT TCT GAG GTT ATC-3’ 
E5.1 R 5’-TCA TTA CAC CAG TTC GTC C-3’ 
E5.2 F 5’-TCA TGT TGC AGC AAT TCA C-3’ 
E5.2 R 5’-CGC CCG CCG CGC CCC GCG CCC GTC CCG CCG CCC CCG CCC 
GAA GAG GAA AGG AAA AAC ATC-3’ 
E6 F 5’-GCG CGT TTC AAT TTG GCT TCT CTT T-3’ 
E6 R 5’-CGC CCG CCG CGC CCC GCG CCC GGC CCG CCG CCC CCG CCC 
GAA ATA ATA AAT AAG AAA ACT GTT CCA ATA C-3’ 
E7 R 5’-CGT CCC GCA ATA CTG GTA TGT ATT TAA C-3’ 
E7 R 5’-CGC CCG CCG CGC CCC GCG CCC GGC CCG CCG CCC CCG CCC 
GGA TAT TTC TCC CAA TGA AAG-3’ 
E8 F 5’-CGG TTT CAC TTT TGG GTA AAT A-3’ 
E8 R 5’-CGC CCG CCG CGC CCC GCG CCC GTC CCG CCG CCC CCG CCC 
GAC CCC CAC AAA ATG TTT AAT-3’ 
E9 F 5’-CGC CCG CCG CGC CCC GCG CCC GGC CCG CCG CCC CCG CCC 
GTC ACT AAA TAG TTT AAG ATG-3’ 
E9 R 5’-TTC ATT CTC TGG ATC AGA GT-3’ 
*GC-clamp portion of primer sequence is underlined 
 
 
 
 25
Table 1.2 – Primer Sequences for LOH analysis. 
LOH Marker Primer Sequence Dye 
D10S1765 F 5’-ACA CTT ACA TAG TGC TTT CTG CG-3’ FAM
D10S1765 R 5’-CAG CCT CCC AAA GTT GC-3’  
AFMa086wg9 F 5’-AAA TGT ACG GTT CAT TGA CTT-3’ HEX 
AFMa086wg9 R 5’-GAC TGA CTA CAA ATG GGC A-3’  
D10S541 F 5’-AAG CAA GTG AAG TCT TAG AAC CAC C-3’ FAM
D10S541 R 5’-CCA CAA GTA ACA GAA AGC CTG TCT C-3’  
D10S583 F 5’-TCT GAC CAA AAT ACC AAA AGA AC-3’ TET 
D10S583 R 5’-AGA GAC TCC AGA TGT TTG ATG A-3’  
 
Table 1.3 – Primer sequences for MSI analysis. 
MSI Marker Primer Sequence Dye 
BAT25 F 5’-TCG CCT CCA AGA ATG TAA GT-3’ TET 
BAT25 R 5’-TCT GCA TTT TAA CTA TGG CTC-3’  
BAT26 F 5’-TGA CTA CTT TTG ACT TCA GCC-3’ FAM 
BAT26 R 5’-AAC CAT TCA ACA TTT TTA ACC C-3’  
D5S346 F 5’-ACT CAC TCT AGT GAT AAA TCG-3’ HEX 
D5S346R 5’-AGC AGA TAA GAC AGT ATT ACT AGT T-3’  
D17S250F 5’-GGA AGA ATC AAA TAG ACA A-3’ TET 
D17S250R 5’-GCT GGC CAT ATA TAT ATT TAA ACC-3’  
D2S123F 5’-AAA CAG GAT GCC TGC CTT TA-3’ HEX 
D2S123R 5’-GGA CTT TCC ACC TAT GGG AC-3’  
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Table 1.4 - Primer sequences and genotyping methodologies for the 10 SNPs. 
SNP       Primer 
Sequence 
Genotyping 
Method 
SNP 1 F CATTCTCAAGCAGGACTCAG 
SNP 1 R AATCCACCTGCTTCAGCTTC 
RFLP 
(HincII) 
SNP 2 F CCTGATGTTTAGAGAAGCAG 
SNP 2 R CTTAGATTGCTGATCTTGTCTCC 
RFLP 
(BfaI) 
SNP 3 F GGATCACAGATGTAGGCTTG 
SNP 3R /FAM/-catcgccTAGCTGAGAGTGTACTAGAC 
Fragment 
Analysis 
SNP4 F AGGAATTCATGTCTGATGTG 
SNP4 R GTGACTGTACTGCTCACTTC 
 SBE primer: gtgcAATCAAATTTTTGTACCTACAA 
 
SNaPshot 
SNP5 F TGTAACCTGCAGGAGGCATC 
SNP5 R AAAGCAGAGAGGTAATACTC 
 SBE primer: attacgtaGACTACGACCCAGGTAGG 
 
SNaPshot 
SNP6 F TGCTTGTTAGAGTGAGGTAG 
SNP6 R CTAGCTCTATCAATCAGGTG 
RFLP 
(NcoI) 
SNP7 F GCAACTGAATAGATGCGTAG 
SNP7 R ATAACTAACACCATCGTCAC 
 SBE primer: cttaatccgtagtcaCCATTACTTCACCTCATCT 
 
SNaPshot 
SNP8 F GGTACCAGGTACCAGATAAG 
SNP8 R AAGGCAATCTGAGTTATCTG 
RFLP 
(HpyCH4IV)
SNP9 F ATTGCTTCGCTCACCTGCTC 
SNP9 R CCTTTGAGATCCTCAGTAAG 
RFLP 
(HpyCH4IV)
SNP10 F TTGGCTACAAATGTCTCTAG 
SNP10 R GGTGCTGCTGTTTACTGAG 
RFLP  
(Bsu36I) 
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Table 2 – Characteristics of the 10 SNPs used in haplotype analysis 
SNP dbSNP ID Position*   
Variation 
(major/minor
allele) 
Location† 
1 rs11202585 89,598,759 G/C -15448 
2 rs1903860 89,610,190 T/C -4017 
3 rs11355437 89,629,037 del/ins G IVS1-14725 
4 rs10887763 89,645,216 A/G IVS2+1370 
5 rs1234224 89,665,276 A/G IVS2-9974 
6 rs10490920 89,675,623 T/C IVS3+329 
7 rs2299941 89,694,699 A/G IVS5-7156 
8 rs52090929 89,710,231 T/C IVS7-400 
9 rs10509532 89,727,534 C/T *12325 
10 rs11202614 89,745,623 C/T *304141 
*SNP position on chromosome 10, March 2006 Human Genome assembly, NCBI 
Build 36.1, (hg18) 
†Location relative to translation start codon (-), PTEN introns (IVS), or translation 
stop codon (*) 
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Table 3 – Somatic PTEN mutations and their consequences. 
 
PTEN 
Mutation                 
PTEN 
Exon 
Sample Histology          FIGO 
Stage 
Consequence 
TTA23GTA 1 AA12 Endometrioid IIIC L23V 
IVS1+35C>T 1 AA6 Endometrioid    IC splicing 
IVS1+35C>T 1 NAA20 Mixed 
mullerian  
IB splicing 
GGA36GAA 2 AA12 Endometrioid IIIC G36E 
CCT38TCT 2 NAA5 Endometrioid IIB P38S 
156insA 2 AA12 Endometrioid IIIC frameshift 
IVS4-30~38delT 5 AA13 Mixed 
epithelial 
IIIC splicing 
IVS4-30~38delT 5 NAA15 Mixed 
mullerian 
IB splicing 
CCA96CGA 5 NAA3 Endometrioid IC P96R 
CTA112GTA 5 AA8 Endometrioid IB L112V 
TGT124TAT 5 AA10 Endometrioid IA C124Y 
GGA127GAA 5 NAA14 Mixed 
epithelial 
IIIC G127E 
CGA130GGA 5 NAA5 Endometrioid IIB R130G 
CGA130TGA 5 AA13 Mixed 
epithelial 
IIIC R130X; truncating 
CGA130TGA 5 NAA11 Endometrioid IB R130X; truncating 
CGA130GGA 5 NAA14 Mixed 
epithelial 
IIIC R130G 
CGA130GGA 5 NAA15 Mixed 
mullerian  
IB R130G 
IVS5+1~5del5 5 AA5 Endometrioid IIB splicing 
610~611delCC 6 NAA15 Mixed 
mullerian 
IB frameshift 
CGA233TGA 7 AA7 Endometrioid IB R233X; truncating 
CGA233TGA 7 AA11 Endometrioid IB R233X; truncating 
795~800delA 7 AA10 Endometrioid IA frameshift 
956~959delCTTT 8 AA5 Endometrioid IIB frameshift 
969insA 8 AA13 Mixed 
epithelial 
IIIC frameshift 
TAC336TAG 8 NAA6 Endometrioid IC Y336X; truncating 
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Table 4.1 – PTEN mutation, LOH, and MSI in relation to race, histology, and FIGO 
tumor stage. 
 
          PTEN Mutation LOH MSI 
Race Freq. P Freq. P Freq. P 
AA 8/26 
(31%) 
15/25 
(60%) 
5/25 
(20%) 
NAA 7/27 
(26%) 
 
0.766 
19/26 
(73%) 
 
0.382 
5/26 
(19%) 
 
1.000 
Histology Freq. P Freq. P Freq. P 
Endometriod 11/24 
(46%) 
15/23 
(60%) 
4/23 
(15%) 
Other 4/29 
(14%) 
 
0.015* 
19/28 
(87%) 
 
1.000 
6/28 
(21%) 
 
1.000 
FIGO Stage Freq. P Freq. P Freq. P 
IA or IB 7/31 
(23%) 
20/29 
(69%) 
4/29 
(14%) 
IC or higher 8/22 
(36%) 
 
0.357 
14/22 
(64%) 
 
0.769 
 6/22 
(27%) 
 
0.295 
 
*When analyzed separately, this association was statistically significant in the AA 
group (P = 0.009), but not in the NAA group (P = 0.662). 
 
Table 4.2 – PTEN Mutation, MSI, and LOH status compared to each other. 
 LOH MSI 
PTEN 
Mutation 
Freq. P Freq. P 
Yes 13/15 
(87%) 
5/15 
(33%) 
No 21/36 
(58%) 
 
0.060 
5/31 
(16%) 
 
0.135 
 
LOH Freq. P 
Yes 9/34 
(26%) 
No 
 
 
 
1/17 
(6%) 
 
0.135 
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Table 5.1 – Pearson χ2  of Reconstructured Haplotypes for AA and NAA 
  Race Histology FIGO Stage 
 Extended 
Haplotypes 
AA 
n = 52 
NAA 
n = 54 
Endo. 
n = 48 
Other 
n = 58 
IA/IB 
n = 60 
>IC 
n = 46 
1 CTIAATATCC 18 13 15 16 22 9 
2 CTDAATACCC 3 9 9 3 7 5 
3 CTIAGTATCC 19 8 10 17 12 15 
4 GCIGGCGTTT 3 8 7 4 5 6 
5 CTDAATATCC 2 6 3 5 6 2 
6 GTIAGTATCC 2 5 3 4 4 3 
7 CTIAATATCT 
8 GCIGGCATTT 
9 CTIAATATTC 
10 GCIGGCATTC 
11 GTIAGCATCC 
12 GTIAGCATTT 
13 GCIAGTATCT 
 
 
 
5 
 
 
 
5 
 
 
 
1 
 
 
 
9 
 
 
 
4 
 
 
 
6 
  χ2  = 13.814, 
P = 0.032 
χ2  = 11.870 
P = 0.065 
χ2  = 7.026 
P = 0.318 
 
  PTEN Mutation LOH MSI 
 Extended 
Haplotypes 
Yes 
n = 30 
No 
n = 74 
Yes 
n = 68 
No 
n = 34 
Yes 
n = 20 
No 
n = 82 
1 CTIAATATCC 7 24 22 9 5 26 
2 CTDAATACCC 4 8 8 4 2 10 
3 CTIAGTATCC 8 18 14 12 4 22 
4 GCIGGCGTTT 6 5 7 4 2 9 
5 CTDAATATCC 1 7 6 0 3 3 
6 GTIAGTATCC 3 4 5 2 1 6 
7 CTIAATATCT 
8 GCIGGCATTT 
9 CTIAATATTC 
10 GCIGGCATTC 
11 GTIAGCATCC 
12 GTIAGCATTT 
13 GCIAGTATCT 
 
 
1 
 
 
8 
 
 
6 
 
 
3 
 
 
3 
 
 
6 
  χ2  = 7.387 
P = 0.287 
χ2  = 5.298 
P = 0.506 
χ2  = 5.329 
P = 0.502 
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Table 5.2 – P-values for Reconstructed Haplotypes 
 Race Histology FIGO Stage 
Hap AA 
n = 52 
(%) 
NAA 
n = 54 
(%) 
P Endo.
n = 48
(%) 
Other 
n = 58 
(%) 
P IA/IB 
n = 60 
(%) 
>IC 
n = 46 
(%) 
P 
1 18 
(35%) 
13 
(24%) 
0.287 16 
(32%) 
15 
(27%) 
0.520 22 
(37%) 
9 
(20%) 
0.084
2 3 
(6%) 
9 
(17%) 
0.124 9 
(18%) 
3 
(5%) 
0.034 7 
(12%) 
5 
(11%) 
1.000
3 19 
(37%) 
8 
(15%) 
0.014 10 
(20%) 
17 
(30%) 
0.375 12 
(20%) 
15 
(33%) 
0.178
4 3 
(6%) 
8 
(15%) 
0.202 7 
(14%) 
4 
(7%) 
0.219 5 
(8%) 
6 
(13%) 
0.526
5 2 
(4%) 
6 
(11%) 
0.271 3 
(6%) 
5 
(9%) 
0.726 6 
(10%) 
2 
(4%) 
0.461
6 2 
(4%) 
5 
(9%) 
0.438 3 
(6%) 
4 
(7%) 
1.000 4 
(7%) 
3 
(7%) 
1.000
7 0 
(0%) 
2 
(4%) 
0.495 0 
(0%) 
2 
(4%) 
0.500 0 
(0%) 
2 
(4%) 
0.186
8 2 
(4%) 
1 
(2%) 
0.614 1 
(2%) 
2 
(4%) 
1.000 2 
(3%) 
1 
(2%) 
1.000
9 0 
(0%) 
1 
(2%) 
1.000 0 
(0%) 
1 
(2%) 
1.000 1 
(2%) 
0 
(0%) 
1.000
10 0 
(0%) 
1 
(2%) 
1.000 0 
(0%) 
1 
(2%) 
1.000 0 
(0%) 
1 
(2%) 
0.433
11 1 
(2%) 
0 
(0%) 
0.491 0 
(0%) 
1 
(2%) 
1.000 0 
(0%) 
1 
(2%) 
0.433
12 1 
(2%) 
0 
(0%) 
0.491 1 
(2%) 
0 
(0%) 
0.453 0 
(0%) 
1 
(2%) 
0.433
13 1 
(2%) 
0 
(0%) 
0.491 0 
(0%) 
1 
(2%) 
1.000 1 
(2%) 
0 
(0%) 
1.000
 
 
Further Analysis of Haplotype 3 
 
 PTEN Mutation LOH MSI 
Hap Yes No P Yes No P Yes No P 
3 8/30 
(27%) 
19/76 
(25%) 
1.000 14/68 
(21%) 
12/34 
(35%) 
0.148 4/20 
(20%) 
22/82 
(27%) 
0.775
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FIGURE LEGENDS 
Figure 1 
Schematic diagram of the PTEN locus with the 4 LOH markers and 10 SNPs included in 
the current analysis. 
 
Figure 2 
LOH status is depicted at each marker (D10S1765, AFMa086wg9, D10S541, and 
D10S583) for all AA and NAA samples. For each sample, overall LOH was scored when 
one or more of the panel of four polymorphic loci showed LOH, as is standard. 
  
Figure 3 
MSI status is provided for each marker (BAT25, BAT26, D2S123, D5S346, and 
D17S250) for all AA and NAA samples. Samples were defined as MSI-positive when at 
least 60% (3 out of 5) of the markers displayed instability. A sample was classified as 
MSI-negative when it did not meet this criterion. 
 
Figure 4 
GOLD plots of pairwise LD between the 10 SNPs in the AA and NAA study groups. D’ 
values are reported for both racial groups. Excluding unique areas of moderate/low LD, 
the data show that the PTEN locus is primarily characterized by strong LD (D’ = 1.00). 
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Figure 4 
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